7060-81-3

Upstream product

• 551-16-6 6-Aminopenicillanic Acid 
• 25629-50-9 3-(2-chlorophenyl)-5-methylisoxazole-4-carbonyl chloride 
• 23598-72-3 3-(2-chlorophenyl)-5-methyl-4-isoxazolecarboxylic acid 
• 4357-94-2 methyl 3-(2'-chlorophenyl)-5-methylisoxazole-4-carboxylate 
• 29568-74-9 2-chloro-N-hydroxybenzimidoyl chloride 
• 3717-28-0 2-chloro benzaldehyde oxime 

Downstream Products

• 22418-07-1 cloxacillin methyl ester 
• 55390-39-1 Cloxacillin S-sulphoxide 
• 83639-10-5 Cloxacillin S-sulphoxide methylester 

Relevant academic research and scientific papers

LIQUID PHARMACEUTICAL FOR ORAL DELIVERY

A liquid pharmaceutical for oral delivery wherein at the time of use, a solid unit dosage form is added to the liquid wherein the unit dosage form is comprised of a substrate soluble in the liquid and a particulate pharmaceutically active material in a pharmaceutically effective amount. At the time of use, the unit dosage form is added to the liquid, without requiring measurement of the liquid, and the entire liquid is consumed to provide for oral delivery of the pharmaceutically effective amount of material.

Method of using deuterated calcium channel blockers

Therapeutic methods and compositions using deuterated enriched 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester and other deuterated dihydropyridine compounds are described. The deuterated compounds exhibit enhanced efficacy in blocking calcium channels over non-deuterated dihydropyridines.

Enhancement of the efficacy of nifedipine by deuteration

A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.